Expression analysis of MIR182 and its associated target genes in advanced ovarian carcinoma

Modern Pathology

Volumn 25, Issue 12, 2012, Pages 1644-1653

  McMillen, Brian D ^a   Aponte, Margarita M ^a   Liu, Zhaojian ^a   Helenowski, Irene B ^a   Scholtens, Denise M ^a   Buttin, Barbara M ^a   Wei, Jian Jun ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

BRCA1; HMGA2; MTSS1; miR 182; ovarian cancer

Indexed keywords

BRCA1 PROTEIN; HIGH MOBILITY GROUP A2 PROTEIN; MICRORNA 182; MTSS1 PROTEIN; PROTEIN; TRANSCRIPTION FACTOR FKHRL1; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES; CANCER GROWTH; CANCER MORTALITY; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARY CANCER; OVERALL SURVIVAL; PARAAORTIC LYMPH NODE; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROGNOSIS; REGULATORY MECHANISM; UTERINE TUBE;

EID: 84870563659     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2012.118     Document Type: Article

References (31)

1. Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010;34:433-443.
2. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol 2006;30:230-236. (Pubitemid 43740193)
3. Levanon K, Crum C, Drapkin R. New insights into the pathogenesis of serous ovarian cancer and its clinical impact. J Clin Oncol 2008;26:5284-5293.
4. Bowtell DD. The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 2010;10: 803-808.
5. Risch HA, McLaughlin JR, Cole DE, et al. Population BRCA1 and BRCA2 mutation frequencies and cancer penetrances: a kin-cohort study in Ontario, Canada. J Natl Cancer Inst 2006;98:1694-1706. (Pubitemid 44942707)
6. Zhang S, Royer R, Li S, et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. Gynecol Oncol 2011;121:353-358.
7. Press JZ, De Luca A, Boyd N, et al. Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer 2008;8:17.
8. Gudmundsdottir K, Ashworth A. The roles of BRCA1 and BRCA2 and associated proteins in the maintenance of genomic stability. Oncogene 2006;25:5864- 5874. (Pubitemid 44453442)
9. Mullan PB, Quinn JE, Harkin DP. The role of BRCA1 in transcriptional regulation and cell cycle control. Oncogene 2006;25:5854-5863. (Pubitemid 44453441)
10. Moskwa P, Buffa FM, Pan Y, et al. miR-182-mediated downregulation of BRCA1 impacts DNA repair and sensitivity to PARP inhibitors. Mol Cell 2011;41: 210-220.
11. Liu Z, Liu J, Segura MF, et al. MiR182 overexpression in tumorigenesis of high-grade ovarian papillary serous carcinoma. J Pathol 2012.
12. Guttilla IK, White BA. Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem 2009;284:23204-23216.
13. Myatt SS, Wang J, Monteiro LJ, et al. Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res 2010;70:367-377.
14. Segura MF, Hanniford D, Menendez S, et al. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci USA 2009;106: 1814-1819.
15. Kloosterman WP, Wienholds E, Ketting RF, et al. Substrate requirements for let-7 function in the developing zebrafish embryo. Nucleic Acids Res 2004;32: 6284-6291. (Pubitemid 40202087)
16. Mahajan A, Liu Z, Gellert L, et al. HMGA2: a biomarker significantly overexpressed in high-grade ovarian serous carcinoma. Mod Pathol 2010;23:673-681.
17. Wei JJ, Wu J, Luan C, et al. HMGA2: a potential biomarker complement to P53 for detection of earlystage high-grade papillary serous carcinoma in fallopian tubes. Am J Surg Pathol 2010;34:18-26.
18. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 2007;211:26-35. (Pubitemid 46092026)
19. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-615.
20. Radosa MP, Hafner N, Camara O, et al. Loss of BRCA1 protein expression as indicator of the BRCAness phenotype is associated with favorable overall survival after complete resection of sporadic ovarian cancer. Int J Gynecol Cancer 2011;21:1399-1406.
21. Carser JE, Quinn JE, Michie CO, et al. BRCA1 is both a prognostic and predictive biomarker of response to chemotherapy in sporadic epithelial ovarian cancer. Gynecol Oncol 2011;123:492-498.
22. Weberpals JI, Tu D, Squire JA, et al. Breast cancer 1 (BRCA1) protein expression as a prognostic marker in sporadic epithelial ovarian carcinoma: an NCIC CTG OV.16 correlative study. Ann Oncol 2011;22: 2403-2410.
23. Vaksman O, Stavnes HT, Kaern J, et al. miRNA profiling along tumor progression in ovarian carcinoma. J Cell Mol Med 2010;15:1593-1602.
24. Wu J, Liu Z, Shao C, et al. HMGA2 overexpressioninduced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res 2011;71:349-359.
25. Ahmed KM, Tsai CY, Lee WH. Derepression of HMGA2 via removal of ZBRK1/BRCA1/CtIP complex enhances mammary tumorigenesis. J Biol Chem 2010;285: 4464-4471.
26. Mayr C, Hemann MT, Bartel DP. Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 2007;315:1576-1579. (Pubitemid 46449474)
27. Wang T, Zhang X, Obijuru L, et al. A micro-RNA signature associated with race, tumor size, and target gene activity in human uterine leiomyomas. Genes Chromosomes Cancer 2007;46:336-347. (Pubitemid 46411325)
28. Weidinger C, Krause K, Klagge A, et al. Forkhead box-O transcription factor: critical conductors of cancer's fate. Endocr Relat Cancer 2008;15:917-929.
29. Fei M, Zhao Y, Wang Y, et al. Low expression of Foxo3a is associated with poor prognosis in ovarian cancer patients. Cancer Invest 2009;27:52-59.
30. Lee YG, Macoska JA, Korenchuk S, et al. MIM, a potential metastasis suppressor gene in bladder cancer. Neoplasia 2002;4:291-294. (Pubitemid 34755838)
31. Parr C, Jiang WG. Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer. Eur J Cancer 2009;45: 1673-1683.